AnaptysBio licenses global rights to BDCA2 modulator antibody portfolio from Centessa for $7M upfront

ANAPTYSBIO, INC

Upfront cash payment of $7M ($4M license fee + $3M for GMP supply of ANB101).
Centessa eligible for $10M milestone at first Phase 3 start and low single-digit royalties.
Anaptys plans to file IND for ANB101 in H2 2024; ANB033 IND expected H1 2024.
Reiterates year-end 2023 cash of $400–410M and cash runway through end of 2026.
ANB101 targets BDCA2 on plasmacytoid dendritic cells for autoimmune/inflammatory diseases.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ANAPTYSBIO, INC entered into License Agreement with Centessa Pharmaceuticals (UK) Limited valued at $7 million (effective 2023-11-24).

Action: entry
Agreement: license
Counterparty: Centessa Pharmaceuticals (UK) Limited
Value: $7 million
Effective: 2023-11-24

Exact text from the filing

On November 24, 2023, AnaptysBio, Inc. (“ Anaptys ”) entered into a License Agreement (the “ License Agreement ”) with Centessa Pharmaceuticals (UK) Limited (“ Centessa ”) pursuant to which Centessa granted to Anaptys an exclusive worldwide license under Centessa’s rights to the blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-23-000069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.